SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    James G. Greene, Causes and Consequences of Degeneration of the Dorsal Motor Nucleus of the Vagus Nerve in Parkinson's Disease, Antioxidants & Redox Signaling, 2014, 21, 4, 649

    CrossRef

  2. 2
    Hande Sariahmetoglu, Aysun Soysal, Aysu Sen, Burcu Yuksel, Sibel Celiker, Beyza Ciftci-Kavaklioglu, Baki Arpaci, Forehead sympathetic skin responses in determining autonomic involvement in Parkinson’s disease, Clinical Neurophysiology, 2014,

    CrossRef

  3. 3
    Kelvin C. Luk, Virginia M.-Y. Lee, Modeling Lewy pathology propagation in Parkinson's disease, Parkinsonism & Related Disorders, 2014, 20, S85

    CrossRef

  4. 4
    Kurt A Jellinger, The pathomechanisms underlying Parkinson's disease, Expert Review of Neurotherapeutics, 2014, 14, 2, 199

    CrossRef

  5. 5
    Raúl de la Fuente-Fernández, A predictive model of neurodegeneration in idiopathic REM-sleep behavior disorder, Parkinsonism & Related Disorders, 2013, 19, 11, 1009

    CrossRef

  6. 6
    Robert E. Burke, Karen O'Malley, Axon degeneration in Parkinson's disease, Experimental Neurology, 2013, 246, 72

    CrossRef

  7. 7
    Suraj Pradhan, Katrin Andreasson, Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease, Experimental Neurology, 2013, 241, 148

    CrossRef

  8. 8
    C. Warren Olanow, Patrik Brundin, Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder?, Movement Disorders, 2013, 28, 1
  9. 9
    Marcelo M.S. Lima, Sleep disturbances in Parkinson's disease: The contribution of dopamine in REM sleep regulation, Sleep Medicine Reviews, 2013, 17, 5, 367

    CrossRef

  10. 10
    D. Garcia-Lorenzo, C. Longo-Dos Santos, C. Ewenczyk, S. Leu-Semenescu, C. Gallea, G. Quattrocchi, P. Pita Lobo, C. Poupon, H. Benali, I. Arnulf, M. Vidailhet, S. Lehericy, The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease, Brain, 2013, 136, 7, 2120

    CrossRef

  11. 11
    Isabel Ubeda-Bañon, Daniel Saiz-Sanchez, Carlos Rosa-Prieto, Alino Martinez-Marcos, α-Synuclein in the olfactory system in Parkinson’s disease: role of neural connections on spreading pathology, Brain Structure and Function, 2013,

    CrossRef

  12. 12
    Sonia George, Nolwen L. Rey, Nicole Reichenbach, Jennifer A. Steiner, Patrik Brundin, α-Synuclein: The Long Distance Runner, Brain Pathology, 2013, 23, 3
  13. 13
    Arif Dalvi, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  14. 14
    Arif Dalvi, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  15. 15
    Douglas E. Hobson, Asymmetry in parkinsonism, spreading pathogens and the nose, Parkinsonism & Related Disorders, 2012, 18, 1, 1

    CrossRef

  16. 16
    Lih-Fen Lue, Douglas G. Walker, Charles H. Adler, Holly Shill, Hung Tran, Haruhiko Akiyama, Lucia I. Sue, John Caviness, Marwan N. Sabbagh, Thomas G. Beach, Biochemical Increase in Phosphorylated Alpha-Synuclein Precedes Histopathology of Lewy-Type Synucleinopathies, Brain Pathology, 2012, 22, 6
  17. 17
    Sara K. Daniel, M. Cecilia Lansang, Michael S. Okun, Bone Mineral Density (BMD) in Male Patients with Parkinson's Disease, International Journal of Neuroscience, 2012, 122, 9, 523

    CrossRef

  18. 18
    Julio C. Aguila, Eva Hedlund, Rosario Sanchez-Pernaute, Cellular Programming and Reprogramming: Sculpting Cell Fate for the Production of Dopamine Neurons for Cell Therapy, Stem Cells International, 2012, 2012, 1

    CrossRef

  19. 19
    Hanna S. Lindgren, Stephen B. Dunnett, Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models?, European Journal of Neuroscience, 2012, 35, 12
  20. 20
    Simone A. van den Berge, Josta T. Kevenaar, Jacqueline A. Sluijs, Elly M. Hol, Dementia in Parkinson's Disease Correlates with α-Synuclein Pathology but Not with Cortical Astrogliosis, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  21. 21
    Amanda N Sacino, Benoit I Giasson, Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?, Alzheimer's Research & Therapy, 2012, 4, 6, 48

    CrossRef

  22. 22
    Glenda Halliday, Heather McCann, Claire Shepherd, Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?, Expert Review of Neurotherapeutics, 2012, 12, 6, 673

    CrossRef

  23. 23
    Arianna Bellucci, Michela Zaltieri, Laura Navarria, Jessica Grigoletto, Cristina Missale, PierFranco Spano, From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease, Brain Research, 2012, 1476, 183

    CrossRef

  24. 24
    Patrick A. Lewis, Mark R. Cookson, Gene expression in the Parkinson's disease brain, Brain Research Bulletin, 2012, 88, 4, 302

    CrossRef

  25. 25
    Taeko Sasai, Tomoyuki Miyamoto, Masayuki Miyamoto, Masaoki Iwanami, Takashi Abe, Masato Matsuura, Yuichi Inoue, Impaired decision-making in idiopathic REM sleep behavior disorder, Sleep Medicine, 2012, 13, 3, 301

    CrossRef

  26. 26
    Aron S. Buchman, Sukriti Nag, Joshua M. Shulman, Andrew S.P. Lim, Veronique G.J.M. VanderHorst, Sue E. Leurgans, Julie A. Schneider, David A. Bennett, Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease, Movement Disorders, 2012, 27, 13
  27. 27
    I. Ferrer, I. López-Gonzalez, M. Carmona, E. Dalfó, A. Pujol, A. Martínez, Neurochemistry and the non-motor aspects of PD, Neurobiology of Disease, 2012, 46, 3, 508

    CrossRef

  28. 28
    Kurt A. Jellinger, Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts, Movement Disorders, 2012, 27, 1
  29. 29
    Shinichi Koyama, Mutsutaka Kobayakawa, Naoko Tachibana, Yuri Masaoka, Ikuo Homma, Kenji Ishii, Mitsuru Kawamura, Neuropsychological and Radiological Assessments of Two Cases with Apparent Idiopathic Rapid Eye Movement Sleep Behaviour Disorder, European Neurology, 2012, 67, 1, 18

    CrossRef

  30. 30
    Rizwan S Akhtar, Matthew B Stern, New concepts in the early and preclinical detection of Parkinson’s disease: therapeutic implications, Expert Review of Neurotherapeutics, 2012, 12, 12, 1429

    CrossRef

  31. 31
    Aron S. Buchman, Joshua M. Shulman, Sukriti Nag, Sue E. Leurgans, Steven E. Arnold, Martha C. Morris, Julie A. Schneider, David A. Bennett, Nigral pathology and parkinsonian signs in elders without Parkinson disease, Annals of Neurology, 2012, 71, 2
  32. 32
    Anna Pilsl, Konstanze F. Winklhofer, Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson’s disease, Acta Neuropathologica, 2012, 123, 2, 173

    CrossRef

  33. 33
    Nico J. Diederich, André Parent, Parkinson's disease: Acquired frailty of archaic neural networks?, Journal of the Neurological Sciences, 2012, 314, 1-2, 143

    CrossRef

  34. 34
    Wilma D.J. van de Berg, Dagmar H. Hepp, Anke A. Dijkstra, J. Annemieke M. Rozemuller, Henk W. Berendse, E. Foncke, Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson's disease, Parkinsonism & Related Disorders, 2012, 18, S28

    CrossRef

  35. 35
    Kurt A. Jellinger, The role of α-synuclein in neurodegeneration — An update, Translational Neuroscience, 2012, 3, 2, 75

    CrossRef

  36. 36
    P. Riederer, J. Sian-Hülsmann, The significance of neuronal lateralisation in Parkinson’s disease, Journal of Neural Transmission, 2012, 119, 8, 953

    CrossRef

  37. 37
    Matthew B. Stern, Anthony Lang, Werner Poewe, Toward a redefinition of Parkinson's disease, Movement Disorders, 2012, 27, 1
  38. 38
    Heiko Braak, Kelly Del Tredici-Braak, Parkinson's Disease, Second Edition, 2012,

    CrossRef

  39. 39
    Thomas Müller, Manfred Gerlach, Moussa B.H. Youdim, Peter Riederer, Neurobiology of Psychiatric Disorders, 2012,

    CrossRef

  40. 40
    Anthony E. Lang, A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials, Movement Disorders, 2011, 26, 5
  41. You have free access to this content41
    Takashi Nomura, Yuichi Inoue, Birgit Högl, Yusuke Uemura, Kenichi Yasui, Taeko Sasai, Kazuyoshi Namba, Kenji Nakashima, Comparison of the clinical features of rapid eye movement sleep behavior disorder in patients with Parkinson's disease and multiple system atrophy, Psychiatry and Clinical Neurosciences, 2011, 65, 3
  42. 42
    Syam Krishnan, Gangadhara Sarma, Sankara Sarma, Asha Kishore, Do nonmotor symptoms in Parkinson's disease differ from normal aging?, Movement Disorders, 2011, 26, 11
  43. 43
    Sueli C.F. Marques, Catarina R. Oliveira, Claudia M.F. Pereira, Tiago F. Outeiro, Epigenetics in neurodegeneration: A new layer of complexity, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 2, 348

    CrossRef

  44. 44
    Lisa Fellner, Kurt A. Jellinger, Gregor K. Wenning, Nadia Stefanova, Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts, Acta Neuropathologica, 2011, 121, 6, 675

    CrossRef

  45. 45
    Roberta Frigerio, Hiroshige Fujishiro, Tae-Beom Ahn, Keith A. Josephs, Demetrius M. Maraganore, Anthony DelleDonne, Joseph E. Parisi, Kevin J. Klos, Bradley F. Boeve, Dennis W. Dickson, J. Eric Ahlskog, Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?, Neurobiology of Aging, 2011, 32, 5, 857

    CrossRef

  46. 46
    Glenda Halliday, Andrew Lees, Matthew Stern, Milestones in Parkinson's disease—Clinical and pathologic features, Movement Disorders, 2011, 26, 6
  47. 47
    Thomas Wichmann, Mahlon R. DeLong, Jorge Guridi, Jose A. Obeso, Milestones in research on the pathophysiology of Parkinson's disease, Movement Disorders, 2011, 26, 6
  48. 48
    Isidro Ferrer, Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1

    CrossRef

  49. 49
    Glenda M. Halliday, Janice L. Holton, Tamas Revesz, Dennis W. Dickson, Neuropathology underlying clinical variability in patients with synucleinopathies, Acta Neuropathologica, 2011, 122, 2, 187

    CrossRef

  50. 50
    Veit Mylius, Juliane Brebbermann, Helena Dohmann, Isabel Engau, Wolfgang H. Oertel, Jens C. Möller, Pain sensitivity and clinical progression in Parkinson's disease, Movement Disorders, 2011, 26, 12
  51. 51
    C. Warren Olanow, K. McNaught, Parkinson's disease, proteins, and prions: Milestones, Movement Disorders, 2011, 26, 6
  52. 52
    Seung-Jae Lee, Hee-Sun Lim, Eliezer Masliah, He-Jin Lee, Protein aggregate spreading in neurodegenerative diseases: Problems and perspectives, Neuroscience Research, 2011, 70, 4, 339

    CrossRef

  53. 53
    Elan D. Louis, Phyllis L. Faust, John-Paul G. Vonsattel, Purkinje cell loss is a characteristic of essential tremor, Parkinsonism & Related Disorders, 2011, 17, 6, 406

    CrossRef

  54. 54
    Jitka Bušková, Jiří Klempíř, Veronika Majerová, Jana Picmausová, Karel Šonka, Robert Jech, Jan Roth, Evžen Růžička, Sleep disturbances in untreated Parkinson’s disease, Journal of Neurology, 2011, 258, 12, 2254

    CrossRef

  55. 55
    Krisztina K. Johansen, Linda R. White, Matthew J. Farrer, Jan O. Aasly, Subclinical signs in LRRK2 mutation carriers, Parkinsonism & Related Disorders, 2011, 17, 7, 528

    CrossRef

  56. 56
    Kurt A. Jellinger, Synuclein deposition and non-motor symptoms in Parkinson disease, Journal of the Neurological Sciences, 2011, 310, 1-2, 107

    CrossRef

  57. 57
    Ai Yamamoto, Anne Simonsen, The elimination of accumulated and aggregated proteins: A role for aggrephagy in neurodegeneration, Neurobiology of Disease, 2011, 43, 1, 17

    CrossRef

  58. 58
    Dalton James Surmeier, Jaime N. Guzman, Javier Sanchez-Padilla, Joshua A. Goldberg, The Origins of Oxidant Stress in Parkinson's Disease and Therapeutic Strategies, Antioxidants & Redox Signaling, 2011, 14, 7, 1289

    CrossRef

  59. 59
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  60. 60
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  61. 61
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef

  62. 62
    Kurt A. Jellinger, Youmans Neurological Surgery, 2011,

    CrossRef

  63. 63
    Christopher H. Hawkes, Kelly Del Tredici, Heiko Braak, A timeline for Parkinson's disease, Parkinsonism & Related Disorders, 2010, 16, 2, 79

    CrossRef

  64. 64
    J. Tong, H. Wong, M. Guttman, L. C. Ang, L. S. Forno, M. Shimadzu, A. H. Rajput, M. D. Muenter, S. J. Kish, O. Hornykiewicz, Y. Furukawa, Brain  -synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation, Brain, 2010, 133, 1, 172

    CrossRef

  65. 65
    Hsiao-Chun Cheng, Christina M. Ulane, Robert E. Burke, Clinical progression in Parkinson disease and the neurobiology of axons, Annals of Neurology, 2010, 67, 6
  66. 66
    David Devos, L. Defebvre, R. Bordet, Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease, Fundamental & Clinical Pharmacology, 2010, 24, 4
  67. 67
    D. Devos, R. Bordet, L. Defebvre, Hypothèses pharmacologiques et prise en charge thérapeutique des troubles de la marche de la maladie de Parkinson, Revue Neurologique, 2010, 166, 2, 168

    CrossRef

  68. 68
    Thomas Holtgraves, Patrick McNamara, Kevin Cappaert, Raymond Durso, Linguistic correlates of asymmetric motor symptom severity in Parkinson’s Disease, Brain and Cognition, 2010, 72, 2, 189

    CrossRef

  69. 69
    F. Viallet, D. Gayraud, B. Bonnefoi, L. Renie, R. Aurenty, Maladie de Parkinson idiopathique : aspects cliniques, diagnostiques et thérapeutiques, EMC - Neurologie, 2010, 7, 2, 1

    CrossRef

  70. 70
    J. Molano, B. Boeve, T. Ferman, G. Smith, J. Parisi, D. Dickson, D. Knopman, N. Graff-Radford, Y. Geda, J. Lucas, K. Kantarci, M. Shiung, C. Jack, M. Silber, V. S. Pankratz, R. Petersen, Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study, Brain, 2010, 133, 2, 540

    CrossRef

  71. 71
    Jose A Obeso, Maria C Rodriguez-Oroz, Christopher G Goetz, Concepcion Marin, Jeffrey H Kordower, Manuel Rodriguez, Etienne C Hirsch, Matthew Farrer, Anthony H V Schapira, Glenda Halliday, Missing pieces in the Parkinson's disease puzzle, Nature Medicine, 2010, 16, 6, 653

    CrossRef

  72. 72
    F. Viallet, D. Gayraud, B. Bonnefoi, L. Renie, R. Aurenty, Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici, EMC - Neurologia, 2010, 10, 3, 1

    CrossRef

  73. 73
    Anthony C. Vernon, Clive Ballard, Michel Modo, Neuroimaging for Lewy body disease: Is the in vivo molecular imaging of α-synuclein neuropathology required and feasible?, Brain Research Reviews, 2010, 65, 1, 28

    CrossRef

  74. 74
    James F Morley, John E Duda, Olfaction as a biomarker in Parkinson’s disease, Biomarkers in Medicine, 2010, 4, 5, 661

    CrossRef

  75. 75
    Stanley Fahn, Parkinson's disease: 10 years of progress, 1997–2007, Movement Disorders, 2010, 25, S1
  76. 76
    Amos D. Korczyn, Tanya Gurevich, Parkinson's disease: Before the motor symptoms and beyond, Journal of the Neurological Sciences, 2010, 289, 1-2, 2

    CrossRef

  77. 77
    B. Zheng, Z. Liao, J. J. Locascio, K. A. Lesniak, S. S. Roderick, M. L. Watt, A. C. Eklund, Y. Zhang-James, P. D. Kim, M. A. Hauser, E. Grunblatt, L. B. Moran, S. A. Mandel, P. Riederer, R. M. Miller, H. J. Federoff, U. Wullner, S. Papapetropoulos, M. B. Youdim, I. Cantuti-Castelvetri, A. B. Young, J. M. Vance, R. L. Davis, J. C. Hedreen, C. H. Adler, T. G. Beach, M. B. Graeber, F. A. Middleton, J.-C. Rochet, C. R. Scherzer, PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease, Science Translational Medicine, 2010, 2, 52, 52ra73

    CrossRef

  78. 78
    Patrik Brundin, Ronald Melki, Ron Kopito, Prion-like transmission of protein aggregates in neurodegenerative diseases, Nature Reviews Molecular Cell Biology, 2010, 11, 4, 301

    CrossRef

  79. 79
    P. A. Kempster, S. S. O'Sullivan, J. L. Holton, T. Revesz, A. J. Lees, Relationships between age and late progression of Parkinson's disease: a clinico-pathological study, Brain, 2010, 133, 6, 1755

    CrossRef

  80. 80
    Bradley F. Boeve, REM sleep behavior disorder, Annals of the New York Academy of Sciences, 2010, 1184, 1
  81. 81
    Anna Paschali, Lambros Messinis, Odysseas Kargiotis, Velissarios Lakiotis, Zinovia Kefalopoulou, Costantinos Constantoyannis, Panagiotis Papathanasopoulos, Pavlos Vassilakos, SPECT neuroimaging and neuropsychological functions in different stages of Parkinson’s disease, European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 6, 1128

    CrossRef

  82. 82
    D. James Surmeier, Jaime N. Guzman, Javier Sanchez-Padilla, Joshua A. Goldberg, Recent Advances in Parkinson’s Disease: Basic Research, 2010,

    CrossRef

  83. 83
    D. James Surmeier, A Lethal Convergence of Dopamine and Calcium, Neuron, 2009, 62, 2, 163

    CrossRef

  84. 84
    Domingo Afonso-Oramas, Ignacio Cruz-Muros, Diego Álvarez de la Rosa, Pedro Abreu, Teresa Giráldez, Javier Castro-Hernández, Josmar Salas-Hernández, José L. Lanciego, Manuel Rodríguez, Tomas González-Hernández, Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease, Neurobiology of Disease, 2009, 36, 3, 494

    CrossRef

  85. 85
    J. R. Crittenden, I. Cantuti-Castelvetri, E. Saka, C. E. Keller-McGandy, L. F. Hernandez, L. R. Kett, A. B. Young, D. G. Standaert, A. M. Graybiel, Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side-effects induced by anti-parkinsonian therapy, Proceedings of the National Academy of Sciences, 2009, 106, 8, 2892

    CrossRef

  86. 86
    Kurt A. Jellinger, Formation and development of Lewy pathology: a critical update, Journal of Neurology, 2009, 256, S3, 270

    CrossRef

  87. 87
    J. Eric Ahlskog, Parkin and PINK1 parkinsonism may represent nigral mitochondrial cytopathies distinct from Lewy body Parkinson's disease, Parkinsonism & Related Disorders, 2009, 15, 10, 721

    CrossRef

  88. 88
    A. H. Schapira, Y. Agid, P. Barone, P. Jenner, M. R. Lemke, W. Poewe, O. Rascol, H. Reichmann, E. Tolosa, Perspectives on recent advances in the understanding and treatment of Parkinson’s disease, European Journal of Neurology, 2009, 16, 10
  89. 89
    Virginie Licker, Enikö Kövari, Denis F. Hochstrasser, Pierre R. Burkhard, Proteomics in human Parkinson's disease research, Journal of Proteomics, 2009, 73, 1, 10

    CrossRef

  90. 90
    Michail E. Kalaitzakis, Ronald K. B. Pearce, The morbid anatomy of dementia in Parkinson’s disease, Acta Neuropathologica, 2009, 118, 5, 587

    CrossRef

  91. 91
    Mark W. Mahowald, Carlos H. Schenck, The REM sleep behavior disorder odyssey, Sleep Medicine Reviews, 2009, 13, 6, 381

    CrossRef

  92. 92
    B.D. van Rooijen, K.A. van Leijenhorst-Groener, M.M.A.E. Claessens, V. Subramaniam, Tryptophan Fluorescence Reveals Structural Features of α-Synuclein Oligomers, Journal of Molecular Biology, 2009, 394, 5, 826

    CrossRef

  93. 93
    Thomas G. Beach, Charles H. Adler, LihFen Lue, Lucia I. Sue, Jyothi Bachalakuri, Jonette Henry-Watson, Jeanne Sasse, Sarah Boyer, Scophil Shirohi, Reed Brooks, Jennifer Eschbacher, Charles L. White, Haru Akiyama, John Caviness, Holly A. Shill, Donald J. Connor, Marwan N. Sabbagh, Douglas G. Walker, Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction, Acta Neuropathologica, 2009, 117, 6, 613

    CrossRef

  94. 94
    Andrew Siderowf, Matthew B. Stern, Premotor Parkinson's disease: Clinical features, detection, and prospects for treatment, Annals of Neurology, 2008, 64, S2
  95. 95
    Dennis W. Dickson, Carolyn F. Orr, Neuropathology of Dementia in Parkinson's Disease,
  96. 96
    Heiko Braak, Kelly Del Tredici, Non-Dopaminergic Pathology of Parkinson's Disease,
  97. 97
    Kurt A. Jellinger, Parkinson's Disease,
  98. 98
    C. Warren Olanow, Fabrizio Stocchi, Anthony E. Lang, The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease,